In this week's episode we’ll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI therapy.
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we’ll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI therapy.
11,140 Listeners
141 Listeners
319 Listeners
500 Listeners
75 Listeners
26 Listeners
1,156 Listeners
2 Listeners
363 Listeners
373 Listeners
1 Listeners
48 Listeners
190 Listeners
30 Listeners
4 Listeners